gastrointestinal (GI)
Scope
Date
~
-
Bio & PharmaGI Innovation transfers allergy treatment tech to Japan
South Korea's GI Innovation Inc. announced on Monday it has transferred its allergy treatment "GI-301" to the Japanese pharmaceutical company Maruho...
Oct 16, 2023 (Gmt+09:00)
-
Bio & PharmaGI Innovation seeks to license allergy therapy to Japan in 2023
South Korea’s GI Innovation Inc. aims to complete licensing of its allergic diseases treatment candidate to a Japanese drug company by year's ...
Jul 17, 2023 (Gmt+09:00)
-
IPOsS.Korean biotech GI Innovation's IPO draws tepid market interest
South Korean biotech GI Innovation Inc. is slated to debut on the local public market at less than half of its pre-IPO investment value, facing luke...
Mar 20, 2023 (Gmt+09:00)
-
Bio & PharmaGI Cell wins approval for human cell management from Korean regulator
GI Cell, a South Korean developer of immune cell therapy products, received a human cell and others management license from South Korean regulatory,...
Dec 27, 2022 (Gmt+09:00)
-
Bio & PharmaS. Korea's GI Cell, Japanese partner to study cell therapy for blood cancer
South Korea's GI Cell, the cell therapy affiliate of GI Innovation, on Tuesday said it signed an agreement with Optieum Biotechnologies of Japan on ...
Dec 14, 2022 (Gmt+09:00)
Latest News
- 1 Seoul appeal: Korean art captivates Indonesia’s affluent connoisseurs
- 2 CJ CheilJedang scraps $3.5 bn green bio sale, shifts gears to expansion
- 3 Trump Jr. meets Korean business chiefs in back-to-back sessions
- 4 Samsung in talks to supply customized HBM4 to Nvidia, Broadcom, Google
- 5 Kookmin Bank raises $700 mn in forex bonds amid strong demand
